Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Riociguat

FDA-approved product (tablet, oral), marketed as Adempas, Riociguat.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Riociguat
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Hypertension
  • Idiopathic and/or familial pulmonary arterial hypertension
  • Pulmonary arterial hypertension
  • Pulmonary hypertension

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antihypertensives for pulmonary arterial hypertension
FDA pharmacologic class
Soluble Guanylate Cyclase Stimulator FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA46.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli32.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae28.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis68.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Riociguat in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Riociguat with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)

    NCT00810693 · start 2008-12-17

    Registered record
    Registry ID
    NCT00810693
    Conditions
    Pulmonary Hypertension
    Interventions
    Riociguat (Adempas, BAY63-2521); Riociguat (Adempas, BAY63-2521); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-12-17
    Completion
    2012-05-14
    Enrolment
    445

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Hypertension
    InterventionRiociguat (Adempas, BAY63-2521); Riociguat (Adempas, BAY63-2521); Placebo
    PhasePhase 3
    Registry statusCompleted

  • Interaction Study in Patients With Pulmonary Hypertension and Stable Treatment of Sildenafil 20 mg TID

    NCT00680654 · start 2008-10

    Registered record
    Registry ID
    NCT00680654
    Conditions
    Hypertension, Pulmonary
    Interventions
    Riociguat (Adempas, BAY63-2521)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-10
    Completion
    2009-11
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension, Pulmonary
    InterventionRiociguat (Adempas, BAY63-2521)
    PhasePhase 1
    Registry statusCompleted

  • Impact of Multiple Doses of BAY63-2521 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Interstitial Lung Disease (ILD) Associated Pulmonary Hypertension (PH)

    NCT00694850 · start 2008-08-02

    Registered record
    Registry ID
    NCT00694850
    Conditions
    Hypertension, Pulmonary
    Interventions
    Riociguat (Adempas, BAY63-2521).
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-08-02
    Completion
    2025-07-03
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension, Pulmonary
    InterventionRiociguat (Adempas, BAY63-2521).
    PhasePhase 2
    Registry statusCompleted

  • COMPERA / COMPERA-KIDS

    NCT01347216 · start 2007-07-01

    Registered record
    Registry ID
    NCT01347216
    Conditions
    Pulmonary Arterial Hypertension (PAH); Pulmonary Hypertension (PH)
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2007-07-01
    Completion
    2026-12-31
    Enrolment
    14,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Arterial Hypertension (PAH); Pulmonary Hypertension (PH)
    InterventionNot recorded
    PhaseNot recorded
    Registry statusRecruiting

  • Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

    NCT01784562

    Registered record
    Registry ID
    NCT01784562
    Conditions
    Hypertension, Pulmonary
    Interventions
    Adempas (Riociguat, BAY63-2521)
    Study type
    EXPANDED_ACCESS
    Phase
    Not recorded
    Registry status
    No longer available
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension, Pulmonary
    InterventionAdempas (Riociguat, BAY63-2521)
    PhaseNot recorded
    Registry statusNo longer available